Drug class
Interleukin-15 superagonist complex; IL-15 receptor agonist immunotherapy
Mechanism of action
A recombinant IL-15 superagonist complex that activates IL-15 receptor signalling on natural killer cells and CD8-positive T cells, promoting their proliferation, activation and antitumour immune responses within the bladder.
General use cases
- In combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, under the US ANKTIVA indication; for intravesical use only
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
